CRVS
NASDAQ · Biotechnology
Corvus Pharmaceuticals Inc
$10.57
+0.74 (+7.53%)
Open$10.29
Previous Close$9.83
Day High$10.59
Day Low$9.77
52W High$26.95
52W Low$6.39
Volume—
Avg Volume968.5K
Market Cap827.33M
P/E Ratio—
EPS$-0.62
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+329.5% upside
Current
$10.57
$10.57
Target
$45.40
$45.40
$29.32
$45.40 avg
$54.46
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 641.17M | 595.25M | 563.38M |
| Net Income | 40.80M | 37.35M | 36.12M |
| Profit Margin | 6.4% | 6.3% | 6.4% |
| EBITDA | 52.52M | 47.56M | 47.46M |
| Free Cash Flow | 29.89M | 29.19M | 29.71M |
| Rev Growth | +19.0% | -0.6% | +17.7% |
| Debt/Equity | 0.54 | 0.42 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |